Profile data is unavailable for this security.
About the company
Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.
- Revenue in USD (TTM)0.00
- Net income in USD-12.23m
- Incorporated2012
- Employees5.00
- LocationSynaptogenix Inc1185 AVENUE OF THE AMERICAS, 3RD FLOORNEW YORK 10036United StatesUSA
- Phone+1 (973) 242-0005
- Fax+1 (302) 655-5049
- Websitehttps://www.synaptogen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lixte Biotechnology Holdings Inc | 0.00 | -4.69m | 5.51m | 3.00 | -- | -- | -- | -- | -2.38 | -2.38 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -118.45 | -104.18 | -130.17 | -111.05 | -- | -- | -- | -- | -- | -1,253.20 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| Biofrontera Inc | 33.25m | -23.09m | 5.52m | 85.00 | -- | -- | -- | 0.1661 | -12.47 | -12.47 | 16.84 | -0.3627 | 0.9995 | 2.50 | 5.75 | 391,200.00 | -69.40 | -- | -144.06 | -- | 48.99 | -- | -69.44 | -- | 0.944 | -3.55 | 4.63 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
| Ainos Inc | 93.68k | -14.56m | 5.53m | 46.00 | -- | 0.2384 | -- | 59.03 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Adial Pharmaceuticals Inc | 0.00 | -11.24m | 5.55m | 4.00 | -- | 0.8677 | -- | -- | -6.01 | -3.75 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -212.33 | -182.35 | -273.26 | -235.45 | -- | -- | -- | -- | -- | -20.20 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Fresh Tracks Therapeutics Inc | 8.01m | -5.69m | 5.56m | 4.00 | -- | 0.5595 | -- | 0.6939 | -1.38 | -1.38 | 1.49 | 1.66 | 0.7326 | -- | -- | 2,001,500.00 | -52.10 | -89.76 | -66.50 | -115.24 | -- | -- | -71.12 | -442.61 | -- | -1,272.00 | 0.00 | -- | 15.31 | 37.62 | 73.02 | -- | -- | -- |
| Clever Leaves Holdings Inc | 17.42m | -19.80m | 5.56m | 296.00 | -- | 0.2262 | -- | 0.3194 | -12.57 | -11.38 | 11.11 | 14.02 | 0.418 | 1.69 | 11.03 | 58,841.21 | -47.51 | -23.20 | -58.14 | -26.55 | 37.64 | -- | -113.66 | -207.52 | 1.63 | -3.70 | 0.0479 | -- | 6.14 | -- | 47.63 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 9.00k | -5.28m | 5.61m | 4.00 | -- | 0.6106 | -- | 623.13 | -3.74 | -3.74 | 0.0064 | 6.81 | 0.0007 | 0.4291 | -- | 2,250.00 | -42.47 | -110.00 | -43.88 | -- | 60.00 | 65.82 | -58,624.33 | -7,961.14 | 23.53 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.34m | 5.65m | 2.00 | -- | -- | -- | -- | -0.0102 | -0.0102 | 0.00 | -0.0002 | 0.00 | -- | -- | -- | -62,992.45 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
| Synaptogenix Inc | 0.00 | -12.23m | 5.69m | 5.00 | -- | 0.2269 | -- | -- | -37.38 | -37.38 | 0.00 | 21.08 | 0.00 | -- | -- | 0.00 | -13.75 | -40.33 | -15.54 | -43.36 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -142.17 | -- | -3.21 | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 5.69m | 15.00 | -- | 0.259 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 5.71m | 389.00 | 0.001 | 0.0001 | 0.6189 | 0.1003 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 5.72m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -15.11m | 5.74m | 7.00 | -- | 0.8327 | -- | -- | -6.46 | -6.46 | 0.00 | 0.8887 | 0.00 | -- | -- | 0.00 | -122.02 | -104.94 | -178.49 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 5.81m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| AiXin Life International Inc | 4.09m | -2.09m | 5.82m | 207.00 | -- | -- | -- | 1.42 | -0.0836 | -0.0836 | 0.1636 | -0.0765 | 0.8268 | 5.43 | 10.02 | 19,757.49 | -42.27 | -16.93 | -- | -34.54 | 16.25 | 48.13 | -51.12 | -36.96 | 0.1515 | -- | -- | -- | 51.00 | 58.08 | 67.18 | -- | 194.59 | -- |
Data as of Jun 14 2024. Currency figures normalised to Synaptogenix Inc's reporting currency: US Dollar USD
4.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Mar 2024 | 16.04k | 1.48% |
| Next Edge Capital Corp.as of 31 Dec 2023 | 12.00k | 1.11% |
| Geode Capital Management LLCas of 31 Mar 2024 | 6.18k | 0.57% |
| Citadel Securities LLCas of 31 Mar 2024 | 3.34k | 0.31% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 3.34k | 0.31% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.74k | 0.25% |
| Platform Technology Partners LLCas of 31 Dec 2023 | 1.01k | 0.09% |
| Elevated Capital Advisors LLCas of 31 Mar 2024 | 838.00 | 0.08% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 804.00 | 0.07% |
| Saxony Capital Management LLCas of 31 Mar 2024 | 800.00 | 0.07% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
